<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216927</url>
  </required_header>
  <id_info>
    <org_study_id>MOD00004808</org_study_id>
    <nct_id>NCT04216927</nct_id>
  </id_info>
  <brief_title>NO During CPB in Neonates to Reduce Risk of AKI</brief_title>
  <official_title>Efficacy of Nitric Oxide Administration During Cardiopulmonary Bypass in Neonates at Reducing the Risk of Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in&#xD;
      children affects up to 60% of high risk-patients and is a major cause of both short- and&#xD;
      long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent&#xD;
      has gained widespread success in preventing this postoperative decline in renal function.&#xD;
      Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent&#xD;
      vasodilator. The investigators hypothesize that nitric oxide, administered during&#xD;
      cardiopulmonary bypass (CPB), may reduce the incidence of AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>• This pilot study is a single center, double-blind, randomized controlled trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AKI</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of AKI in the first 72 hours postoperative as defined by the Kidney Disease Improving Global Outcomes (KDIGO) diagnostic classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker evidence of AKI - NGAL</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker neutrophil gelatinase-associated lipocalin (NGAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker evidence of AKI - KIM-1</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker kidney injury molecule-1 (KIM-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker evidence of AKI - IL-18</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker interleukin-18 (IL-18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker evidence of AKI - L-FABP</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker liver-type fatty acid-binding protein (L-FABP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker evidence of AKI - urinary nitrite</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker urinary nitrate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on GFR</measure>
    <time_frame>72 hours</time_frame>
    <description>Postoperative GFR measured using serum cystatin C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Cardiac Output</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence of low cardiac output syndrome (LCOS) during the first 48 hours postoperative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>AKI</condition>
  <condition>CHD - Congenital Heart Disease</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard CPB without NO administered at any point intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit</description>
    <arm_group_label>Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen alone will be entrained for placebo arm</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All neonates (≤31 days) undergoing cardiac surgery with CPB for CHD will be deemed&#xD;
             eligible for enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to obtain informed consent from parent/guardian&#xD;
&#xD;
          2. Clinical signs of preoperative persistent elevated pulmonary vascular resistance,&#xD;
&#xD;
          3. Emergency surgery,&#xD;
&#xD;
          4. Episode of cardiac arrest within 1 week before surgery,&#xD;
&#xD;
          5. Recent treatment with steroids and/or a condition that may require treatment with&#xD;
             steroids (excluding steroid administration specifically for CPB),&#xD;
&#xD;
          6. Use of inhaled NO (iNO) immediately prior to surgery,&#xD;
&#xD;
          7. Structural renal abnormalities by ultrasound,&#xD;
&#xD;
          8. Preoperative AKI,&#xD;
&#xD;
          9. Use of other investigational drugs,&#xD;
&#xD;
         10. Weight less than &lt;2 kg,&#xD;
&#xD;
         11. Gestational age &lt;36 weeks,&#xD;
&#xD;
         12. Major extracardiac congenital anomalies,&#xD;
&#xD;
         13. Non-English speakers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>31 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David S Cooepr, MD</last_name>
    <phone>5138035448</phone>
    <email>David.Cooper@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Cooper, MD</last_name>
      <phone>513-803-5448</phone>
      <email>David.Cooper@cchmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

